Loading…

Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim

In this pre-clinical in vitro study conducted in estrogen receptor positive (ER+) breast cancer cells, we have characterized the effects of insulin-like growth factor I (IGF-1) on the cytostatic and cytotoxic action of antiestrogen treatment when used as a single agent or in combination with the ant...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research : BCR 2012-03, Vol.14 (2), p.R52-R52, Article R52
Main Authors: Periyasamy-Thandavan, Sudharsan, Takhar, Suchreet, Singer, Adam, Dohn, Michael Robert, Jackson, William Hutch, Welborn, April Eve, LeRoith, Derek, Marrero, Mario, Thangaraju, Muthusamy, Huang, Shuang, Schoenlein, Patricia Veronica
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83
cites cdi_FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83
container_end_page R52
container_issue 2
container_start_page R52
container_title Breast cancer research : BCR
container_volume 14
creator Periyasamy-Thandavan, Sudharsan
Takhar, Suchreet
Singer, Adam
Dohn, Michael Robert
Jackson, William Hutch
Welborn, April Eve
LeRoith, Derek
Marrero, Mario
Thangaraju, Muthusamy
Huang, Shuang
Schoenlein, Patricia Veronica
description In this pre-clinical in vitro study conducted in estrogen receptor positive (ER+) breast cancer cells, we have characterized the effects of insulin-like growth factor I (IGF-1) on the cytostatic and cytotoxic action of antiestrogen treatment when used as a single agent or in combination with the antiprogestin mifepristone (MIF). Our goal was to identify new molecular targets to improve the efficacy of hormonal therapy in breast cancer patients that have a poor response to hormonal therapy, in part, due to high circulating levels of unbound insulinIGF-1. IGF-1-mediated effects on cytostasis and apoptotic cell death were determined with cell counts conducted in the presence and absence of trypan blue; enzyme-linked immunosorbent assays to determine the intracellular levels of cleaved cytokeratin 18, a marker of epithelial cancer cell apoptosis; and immunoblot analysis to determine the levels of cleaved poly-ADP ribose polymerase (PARP) and lamin A that result from caspase-dependent apoptosis. Cytotoxicity was further characterized by determination of the levels of reactive oxygen species (ROS) and the percent of mitochondrial membrane depolarization in cell populations treated with the different hormones in the presence and absence of IGF-1. Small molecule inhibitors of the dual-specificity protein kinase MEK1, MEK1 siRNA, Bim siRNA, and vectors overexpressing MEK1 wild type and mutant, dominant negative cDNA were used to identify key IGF-1 downstream prosurvival effectors. IGF-1, at physiologically relevant levels, blocked the cytotoxic action(s) of the antiestrogens 4-hydroxytamoxifen (4-OHT) and tamoxifen (TAM) when used as single agents or in combination with the antiprogestin MIF. The antiapoptotic action of IGF-1 was mediated primarily through the action of MEK1. MEK1 expression reduced the levels of ROS and mitochondrial membrane depolarization induced by the hormonal treatments via a mechanism that involved the phosphorylation and proteasomal turnover of the proapoptotic BH3-only Bcl-2 family member Bim. Importantly, small-molecule inhibitors of MEK1 circumvented the prosurvival action of IGF-1 by restoring Bim to levels that more effectively mediated apoptosis in ER+ breast cancer cells. his study provides strong support for the use of MEK1 inhibitors in combination with hormonal therapy to effectively affect cytostasis and activate a Bim-dependent apoptotic pathway in ER+ breast cancer cells. We discuss that MEK1 blockade may be a particularly effe
doi_str_mv 10.1186/bcr3153
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3446386</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A478424654</galeid><sourcerecordid>A478424654</sourcerecordid><originalsourceid>FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83</originalsourceid><addsrcrecordid>eNp1ktGK1DAUhoso7rqKbyABLxSka9KmbcYLYXcZdxdXBFHwLiTpSSfaJjVJlXks39B0Oy4zoOQiOSf__-VwcrLsKcGnhLD6tVS-JFV5LzsmtK7yihZf7--dj7JHIXzDmDSsYg-zo6KgxYquyHH2-9qGqTc27813QJ13v-IGaaGi84ggESPYSUQISNhoIETvOrB5itrbzDjHISa_se2kIGVHN0YXTEDGovWnV0h6ECEiJawCjxT0fUByiz6s3xPkoZt6EY2zyGkUN4DOr8rc2X6LEjlfWNGoOYqQgOdmeJw90KIP8GS3n2Rf3q0_X1zlNx8vry_ObnJJWRNzRXGtCBECQ1UVZdsqSTFo0TQEQ8sUoZKJlrZEMtZotdKKyJJWDDdSVLpl5Un2duGOkxygVWCjFz0fvRmE33InDD-8sWbDO_eTl5TWJasT4M0CkMb9B3B4o9zAdx-ZzC93r3v3Y0ot5oMJc_OEBTcFTjAlZUEJxkn6fJF2ogdurHaJpmY5P6MNo0WaAppUp_9QpdXCYJSzoE3KHxheLAblXQge9F3lBPN56PZqfbbfqTvd3ykr_wBRBtds</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1041324100</pqid></control><display><type>article</type><title>Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim</title><source>PubMed Central</source><creator>Periyasamy-Thandavan, Sudharsan ; Takhar, Suchreet ; Singer, Adam ; Dohn, Michael Robert ; Jackson, William Hutch ; Welborn, April Eve ; LeRoith, Derek ; Marrero, Mario ; Thangaraju, Muthusamy ; Huang, Shuang ; Schoenlein, Patricia Veronica</creator><creatorcontrib>Periyasamy-Thandavan, Sudharsan ; Takhar, Suchreet ; Singer, Adam ; Dohn, Michael Robert ; Jackson, William Hutch ; Welborn, April Eve ; LeRoith, Derek ; Marrero, Mario ; Thangaraju, Muthusamy ; Huang, Shuang ; Schoenlein, Patricia Veronica</creatorcontrib><description>In this pre-clinical in vitro study conducted in estrogen receptor positive (ER+) breast cancer cells, we have characterized the effects of insulin-like growth factor I (IGF-1) on the cytostatic and cytotoxic action of antiestrogen treatment when used as a single agent or in combination with the antiprogestin mifepristone (MIF). Our goal was to identify new molecular targets to improve the efficacy of hormonal therapy in breast cancer patients that have a poor response to hormonal therapy, in part, due to high circulating levels of unbound insulinIGF-1. IGF-1-mediated effects on cytostasis and apoptotic cell death were determined with cell counts conducted in the presence and absence of trypan blue; enzyme-linked immunosorbent assays to determine the intracellular levels of cleaved cytokeratin 18, a marker of epithelial cancer cell apoptosis; and immunoblot analysis to determine the levels of cleaved poly-ADP ribose polymerase (PARP) and lamin A that result from caspase-dependent apoptosis. Cytotoxicity was further characterized by determination of the levels of reactive oxygen species (ROS) and the percent of mitochondrial membrane depolarization in cell populations treated with the different hormones in the presence and absence of IGF-1. Small molecule inhibitors of the dual-specificity protein kinase MEK1, MEK1 siRNA, Bim siRNA, and vectors overexpressing MEK1 wild type and mutant, dominant negative cDNA were used to identify key IGF-1 downstream prosurvival effectors. IGF-1, at physiologically relevant levels, blocked the cytotoxic action(s) of the antiestrogens 4-hydroxytamoxifen (4-OHT) and tamoxifen (TAM) when used as single agents or in combination with the antiprogestin MIF. The antiapoptotic action of IGF-1 was mediated primarily through the action of MEK1. MEK1 expression reduced the levels of ROS and mitochondrial membrane depolarization induced by the hormonal treatments via a mechanism that involved the phosphorylation and proteasomal turnover of the proapoptotic BH3-only Bcl-2 family member Bim. Importantly, small-molecule inhibitors of MEK1 circumvented the prosurvival action of IGF-1 by restoring Bim to levels that more effectively mediated apoptosis in ER+ breast cancer cells. his study provides strong support for the use of MEK1 inhibitors in combination with hormonal therapy to effectively affect cytostasis and activate a Bim-dependent apoptotic pathway in ER+ breast cancer cells. We discuss that MEK1 blockade may be a particularly effective treatment for women with high circulating levels of IGF-1, which have been correlated to a poor prognosis.</description><identifier>ISSN: 1465-542X</identifier><identifier>ISSN: 1465-5411</identifier><identifier>EISSN: 1465-542X</identifier><identifier>DOI: 10.1186/bcr3153</identifier><identifier>PMID: 22429491</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Apoptosis ; Apoptosis - drug effects ; Apoptosis Regulatory Proteins - metabolism ; Bcl-2-Like Protein 11 ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Cancer cells ; Cancer treatment ; Care and treatment ; Cell Line, Tumor ; Enzyme Inhibitors - pharmacology ; Enzymes ; Estrogen Antagonists - pharmacology ; Estrogen Receptor Modulators - pharmacology ; Estrogens ; Female ; Health aspects ; Hormone Antagonists - pharmacology ; Humans ; Insulin-Like Growth Factor I - metabolism ; Insulin-Like Growth Factor I - pharmacology ; Keratin ; MAP Kinase Kinase 1 - antagonists &amp; inhibitors ; MAP Kinase Kinase 1 - genetics ; MAP Kinase Kinase 1 - metabolism ; Membrane Proteins - metabolism ; Mifepristone - pharmacology ; Monosaccharides ; Oxidative Stress - drug effects ; Phosphorylation - drug effects ; Proto-Oncogene Proteins - metabolism ; Reactive Oxygen Species - metabolism ; Receptors, Estrogen - metabolism ; Tamoxifen - analogs &amp; derivatives ; Tamoxifen - pharmacology</subject><ispartof>Breast cancer research : BCR, 2012-03, Vol.14 (2), p.R52-R52, Article R52</ispartof><rights>COPYRIGHT 2012 BioMed Central Ltd.</rights><rights>Copyright ©2012 Schoenlein et al.; licensee BioMed Central Ltd. 2012 Schoenlein et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83</citedby><cites>FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446386/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446386/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22429491$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Periyasamy-Thandavan, Sudharsan</creatorcontrib><creatorcontrib>Takhar, Suchreet</creatorcontrib><creatorcontrib>Singer, Adam</creatorcontrib><creatorcontrib>Dohn, Michael Robert</creatorcontrib><creatorcontrib>Jackson, William Hutch</creatorcontrib><creatorcontrib>Welborn, April Eve</creatorcontrib><creatorcontrib>LeRoith, Derek</creatorcontrib><creatorcontrib>Marrero, Mario</creatorcontrib><creatorcontrib>Thangaraju, Muthusamy</creatorcontrib><creatorcontrib>Huang, Shuang</creatorcontrib><creatorcontrib>Schoenlein, Patricia Veronica</creatorcontrib><title>Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim</title><title>Breast cancer research : BCR</title><addtitle>Breast Cancer Res</addtitle><description>In this pre-clinical in vitro study conducted in estrogen receptor positive (ER+) breast cancer cells, we have characterized the effects of insulin-like growth factor I (IGF-1) on the cytostatic and cytotoxic action of antiestrogen treatment when used as a single agent or in combination with the antiprogestin mifepristone (MIF). Our goal was to identify new molecular targets to improve the efficacy of hormonal therapy in breast cancer patients that have a poor response to hormonal therapy, in part, due to high circulating levels of unbound insulinIGF-1. IGF-1-mediated effects on cytostasis and apoptotic cell death were determined with cell counts conducted in the presence and absence of trypan blue; enzyme-linked immunosorbent assays to determine the intracellular levels of cleaved cytokeratin 18, a marker of epithelial cancer cell apoptosis; and immunoblot analysis to determine the levels of cleaved poly-ADP ribose polymerase (PARP) and lamin A that result from caspase-dependent apoptosis. Cytotoxicity was further characterized by determination of the levels of reactive oxygen species (ROS) and the percent of mitochondrial membrane depolarization in cell populations treated with the different hormones in the presence and absence of IGF-1. Small molecule inhibitors of the dual-specificity protein kinase MEK1, MEK1 siRNA, Bim siRNA, and vectors overexpressing MEK1 wild type and mutant, dominant negative cDNA were used to identify key IGF-1 downstream prosurvival effectors. IGF-1, at physiologically relevant levels, blocked the cytotoxic action(s) of the antiestrogens 4-hydroxytamoxifen (4-OHT) and tamoxifen (TAM) when used as single agents or in combination with the antiprogestin MIF. The antiapoptotic action of IGF-1 was mediated primarily through the action of MEK1. MEK1 expression reduced the levels of ROS and mitochondrial membrane depolarization induced by the hormonal treatments via a mechanism that involved the phosphorylation and proteasomal turnover of the proapoptotic BH3-only Bcl-2 family member Bim. Importantly, small-molecule inhibitors of MEK1 circumvented the prosurvival action of IGF-1 by restoring Bim to levels that more effectively mediated apoptosis in ER+ breast cancer cells. his study provides strong support for the use of MEK1 inhibitors in combination with hormonal therapy to effectively affect cytostasis and activate a Bim-dependent apoptotic pathway in ER+ breast cancer cells. We discuss that MEK1 blockade may be a particularly effective treatment for women with high circulating levels of IGF-1, which have been correlated to a poor prognosis.</description><subject>Analysis</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis Regulatory Proteins - metabolism</subject><subject>Bcl-2-Like Protein 11</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer cells</subject><subject>Cancer treatment</subject><subject>Care and treatment</subject><subject>Cell Line, Tumor</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Enzymes</subject><subject>Estrogen Antagonists - pharmacology</subject><subject>Estrogen Receptor Modulators - pharmacology</subject><subject>Estrogens</subject><subject>Female</subject><subject>Health aspects</subject><subject>Hormone Antagonists - pharmacology</subject><subject>Humans</subject><subject>Insulin-Like Growth Factor I - metabolism</subject><subject>Insulin-Like Growth Factor I - pharmacology</subject><subject>Keratin</subject><subject>MAP Kinase Kinase 1 - antagonists &amp; inhibitors</subject><subject>MAP Kinase Kinase 1 - genetics</subject><subject>MAP Kinase Kinase 1 - metabolism</subject><subject>Membrane Proteins - metabolism</subject><subject>Mifepristone - pharmacology</subject><subject>Monosaccharides</subject><subject>Oxidative Stress - drug effects</subject><subject>Phosphorylation - drug effects</subject><subject>Proto-Oncogene Proteins - metabolism</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Tamoxifen - analogs &amp; derivatives</subject><subject>Tamoxifen - pharmacology</subject><issn>1465-542X</issn><issn>1465-5411</issn><issn>1465-542X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp1ktGK1DAUhoso7rqKbyABLxSka9KmbcYLYXcZdxdXBFHwLiTpSSfaJjVJlXks39B0Oy4zoOQiOSf__-VwcrLsKcGnhLD6tVS-JFV5LzsmtK7yihZf7--dj7JHIXzDmDSsYg-zo6KgxYquyHH2-9qGqTc27813QJ13v-IGaaGi84ggESPYSUQISNhoIETvOrB5itrbzDjHISa_se2kIGVHN0YXTEDGovWnV0h6ECEiJawCjxT0fUByiz6s3xPkoZt6EY2zyGkUN4DOr8rc2X6LEjlfWNGoOYqQgOdmeJw90KIP8GS3n2Rf3q0_X1zlNx8vry_ObnJJWRNzRXGtCBECQ1UVZdsqSTFo0TQEQ8sUoZKJlrZEMtZotdKKyJJWDDdSVLpl5Un2duGOkxygVWCjFz0fvRmE33InDD-8sWbDO_eTl5TWJasT4M0CkMb9B3B4o9zAdx-ZzC93r3v3Y0ot5oMJc_OEBTcFTjAlZUEJxkn6fJF2ogdurHaJpmY5P6MNo0WaAppUp_9QpdXCYJSzoE3KHxheLAblXQge9F3lBPN56PZqfbbfqTvd3ykr_wBRBtds</recordid><startdate>20120319</startdate><enddate>20120319</enddate><creator>Periyasamy-Thandavan, Sudharsan</creator><creator>Takhar, Suchreet</creator><creator>Singer, Adam</creator><creator>Dohn, Michael Robert</creator><creator>Jackson, William Hutch</creator><creator>Welborn, April Eve</creator><creator>LeRoith, Derek</creator><creator>Marrero, Mario</creator><creator>Thangaraju, Muthusamy</creator><creator>Huang, Shuang</creator><creator>Schoenlein, Patricia Veronica</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120319</creationdate><title>Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim</title><author>Periyasamy-Thandavan, Sudharsan ; Takhar, Suchreet ; Singer, Adam ; Dohn, Michael Robert ; Jackson, William Hutch ; Welborn, April Eve ; LeRoith, Derek ; Marrero, Mario ; Thangaraju, Muthusamy ; Huang, Shuang ; Schoenlein, Patricia Veronica</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Analysis</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis Regulatory Proteins - metabolism</topic><topic>Bcl-2-Like Protein 11</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer cells</topic><topic>Cancer treatment</topic><topic>Care and treatment</topic><topic>Cell Line, Tumor</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Enzymes</topic><topic>Estrogen Antagonists - pharmacology</topic><topic>Estrogen Receptor Modulators - pharmacology</topic><topic>Estrogens</topic><topic>Female</topic><topic>Health aspects</topic><topic>Hormone Antagonists - pharmacology</topic><topic>Humans</topic><topic>Insulin-Like Growth Factor I - metabolism</topic><topic>Insulin-Like Growth Factor I - pharmacology</topic><topic>Keratin</topic><topic>MAP Kinase Kinase 1 - antagonists &amp; inhibitors</topic><topic>MAP Kinase Kinase 1 - genetics</topic><topic>MAP Kinase Kinase 1 - metabolism</topic><topic>Membrane Proteins - metabolism</topic><topic>Mifepristone - pharmacology</topic><topic>Monosaccharides</topic><topic>Oxidative Stress - drug effects</topic><topic>Phosphorylation - drug effects</topic><topic>Proto-Oncogene Proteins - metabolism</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Tamoxifen - analogs &amp; derivatives</topic><topic>Tamoxifen - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Periyasamy-Thandavan, Sudharsan</creatorcontrib><creatorcontrib>Takhar, Suchreet</creatorcontrib><creatorcontrib>Singer, Adam</creatorcontrib><creatorcontrib>Dohn, Michael Robert</creatorcontrib><creatorcontrib>Jackson, William Hutch</creatorcontrib><creatorcontrib>Welborn, April Eve</creatorcontrib><creatorcontrib>LeRoith, Derek</creatorcontrib><creatorcontrib>Marrero, Mario</creatorcontrib><creatorcontrib>Thangaraju, Muthusamy</creatorcontrib><creatorcontrib>Huang, Shuang</creatorcontrib><creatorcontrib>Schoenlein, Patricia Veronica</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast cancer research : BCR</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Periyasamy-Thandavan, Sudharsan</au><au>Takhar, Suchreet</au><au>Singer, Adam</au><au>Dohn, Michael Robert</au><au>Jackson, William Hutch</au><au>Welborn, April Eve</au><au>LeRoith, Derek</au><au>Marrero, Mario</au><au>Thangaraju, Muthusamy</au><au>Huang, Shuang</au><au>Schoenlein, Patricia Veronica</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim</atitle><jtitle>Breast cancer research : BCR</jtitle><addtitle>Breast Cancer Res</addtitle><date>2012-03-19</date><risdate>2012</risdate><volume>14</volume><issue>2</issue><spage>R52</spage><epage>R52</epage><pages>R52-R52</pages><artnum>R52</artnum><issn>1465-542X</issn><issn>1465-5411</issn><eissn>1465-542X</eissn><abstract>In this pre-clinical in vitro study conducted in estrogen receptor positive (ER+) breast cancer cells, we have characterized the effects of insulin-like growth factor I (IGF-1) on the cytostatic and cytotoxic action of antiestrogen treatment when used as a single agent or in combination with the antiprogestin mifepristone (MIF). Our goal was to identify new molecular targets to improve the efficacy of hormonal therapy in breast cancer patients that have a poor response to hormonal therapy, in part, due to high circulating levels of unbound insulinIGF-1. IGF-1-mediated effects on cytostasis and apoptotic cell death were determined with cell counts conducted in the presence and absence of trypan blue; enzyme-linked immunosorbent assays to determine the intracellular levels of cleaved cytokeratin 18, a marker of epithelial cancer cell apoptosis; and immunoblot analysis to determine the levels of cleaved poly-ADP ribose polymerase (PARP) and lamin A that result from caspase-dependent apoptosis. Cytotoxicity was further characterized by determination of the levels of reactive oxygen species (ROS) and the percent of mitochondrial membrane depolarization in cell populations treated with the different hormones in the presence and absence of IGF-1. Small molecule inhibitors of the dual-specificity protein kinase MEK1, MEK1 siRNA, Bim siRNA, and vectors overexpressing MEK1 wild type and mutant, dominant negative cDNA were used to identify key IGF-1 downstream prosurvival effectors. IGF-1, at physiologically relevant levels, blocked the cytotoxic action(s) of the antiestrogens 4-hydroxytamoxifen (4-OHT) and tamoxifen (TAM) when used as single agents or in combination with the antiprogestin MIF. The antiapoptotic action of IGF-1 was mediated primarily through the action of MEK1. MEK1 expression reduced the levels of ROS and mitochondrial membrane depolarization induced by the hormonal treatments via a mechanism that involved the phosphorylation and proteasomal turnover of the proapoptotic BH3-only Bcl-2 family member Bim. Importantly, small-molecule inhibitors of MEK1 circumvented the prosurvival action of IGF-1 by restoring Bim to levels that more effectively mediated apoptosis in ER+ breast cancer cells. his study provides strong support for the use of MEK1 inhibitors in combination with hormonal therapy to effectively affect cytostasis and activate a Bim-dependent apoptotic pathway in ER+ breast cancer cells. We discuss that MEK1 blockade may be a particularly effective treatment for women with high circulating levels of IGF-1, which have been correlated to a poor prognosis.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>22429491</pmid><doi>10.1186/bcr3153</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1465-542X
ispartof Breast cancer research : BCR, 2012-03, Vol.14 (2), p.R52-R52, Article R52
issn 1465-542X
1465-5411
1465-542X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3446386
source PubMed Central
subjects Analysis
Apoptosis
Apoptosis - drug effects
Apoptosis Regulatory Proteins - metabolism
Bcl-2-Like Protein 11
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Cancer cells
Cancer treatment
Care and treatment
Cell Line, Tumor
Enzyme Inhibitors - pharmacology
Enzymes
Estrogen Antagonists - pharmacology
Estrogen Receptor Modulators - pharmacology
Estrogens
Female
Health aspects
Hormone Antagonists - pharmacology
Humans
Insulin-Like Growth Factor I - metabolism
Insulin-Like Growth Factor I - pharmacology
Keratin
MAP Kinase Kinase 1 - antagonists & inhibitors
MAP Kinase Kinase 1 - genetics
MAP Kinase Kinase 1 - metabolism
Membrane Proteins - metabolism
Mifepristone - pharmacology
Monosaccharides
Oxidative Stress - drug effects
Phosphorylation - drug effects
Proto-Oncogene Proteins - metabolism
Reactive Oxygen Species - metabolism
Receptors, Estrogen - metabolism
Tamoxifen - analogs & derivatives
Tamoxifen - pharmacology
title Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T21%3A48%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insulin-like%20growth%20factor%201%20attenuates%20antiestrogen-%20and%20antiprogestin-induced%20apoptosis%20in%20ER+%20breast%20cancer%20cells%20by%20MEK1%20regulation%20of%20the%20BH3-only%20pro-apoptotic%20protein%20Bim&rft.jtitle=Breast%20cancer%20research%20:%20BCR&rft.au=Periyasamy-Thandavan,%20Sudharsan&rft.date=2012-03-19&rft.volume=14&rft.issue=2&rft.spage=R52&rft.epage=R52&rft.pages=R52-R52&rft.artnum=R52&rft.issn=1465-542X&rft.eissn=1465-542X&rft_id=info:doi/10.1186/bcr3153&rft_dat=%3Cgale_pubme%3EA478424654%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1041324100&rft_id=info:pmid/22429491&rft_galeid=A478424654&rfr_iscdi=true